Antiangiogenic agents.
Stani
Simonetta Chiara
SC
Azienda Ospedaliera San Filippo Neri, Rome, Italy.
Capaccetti
Barbara
B
Bonginelli
Paola
P
Sarmiento
Roberta
R
De Sio
Livia
L
Fanelli
Massimo
M
Gasparini
Giampietro
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000098:blood supply* / Q000188:drug therapy; D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004815:Epidermal Growth Factor / Q000037:antagonists & inhibitors; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008175:Lung Neoplasms / Q000098:blood supply* / Q000188:drug therapy; D061965:Matrix Metalloproteinase Inhibitors; D008565:Membrane Proteins; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D011451:Prostaglandin-Endoperoxide Synthases; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D051546:Cyclooxygenase 2; D004791:Enzyme Inhibitors; D004815:Epidermal Growth Factor; D007527:Isoenzymes; D061965:Matrix Metalloproteinase Inhibitors; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D018719:Erb-b2 Receptor Tyrosine Kinases; C496540:PTGS2 protein, human